A fixed-dose combination of rosuvastatin and amlodipine – examples of treatment scenarios Case report
Article Sidebar
Published:
Dec 31, 2016
Keywords:
arterial hypertension, dyslipidaemia, rosuvastatin, amlodipine, fixed-dose combination
Main Article Content
Abstract
Patients taking antihypertensive drugs often require the use of lipid-lowering drugs. A fixed-dose combination of rosuvastatin and amlodipine is convenient and efficient solution for improving compliance in patients with arterial hypertension and concomitant lipid disorders. The article presents examples of treatment scenarios for the use of such a combination.
Article Details
How to Cite
Barylski, M. (2016). A fixed-dose combination of rosuvastatin and amlodipine – examples of treatment scenarios. Medycyna Faktow (J EBM), 9(4(33), 334-337. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2208
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wożakowska-Kapłon B., Filipiak K.J., Mamcarz A. et al.: Aktualne problemy terapii dyslipidemii w Polsce – II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol. Pol. 2014; 72: 847-853.
2. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
3. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
4. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk. Manag. 2008; 4: 673-678.
5. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc. Disord. 2010; 10: 29.
6. Zdrojewski T., Jankowski P., Bandosz P. et al.: Nowa wersja systemu oceny ryzyka sercowo-naczyniowego i tablic SCORE dla populacji Polski. Kardiol. Pol. 2015; 73(10): 958-961.
7. Catapano A.L., Graham I., De Backer G. et al.; Task Force Members; Additional Contributor: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016 Aug 27. pii: ehw272 [złożone do druku].
8. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
9. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006- -2010. Med. J. Aust. 2011; 195(3): 134-137.
2. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
3. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
4. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk. Manag. 2008; 4: 673-678.
5. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc. Disord. 2010; 10: 29.
6. Zdrojewski T., Jankowski P., Bandosz P. et al.: Nowa wersja systemu oceny ryzyka sercowo-naczyniowego i tablic SCORE dla populacji Polski. Kardiol. Pol. 2015; 73(10): 958-961.
7. Catapano A.L., Graham I., De Backer G. et al.; Task Force Members; Additional Contributor: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016 Aug 27. pii: ehw272 [złożone do druku].
8. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
9. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006- -2010. Med. J. Aust. 2011; 195(3): 134-137.